title: Optimal use of targeted agents for advanced gastrointestinal stromal tumours.
abstract: Imatinib is the recommended 1st-line treatment for a KIT-positive unresectable and/or metastatic gastrointestinal stromal tumour (GIST). However, some patients experience intolerance to imatinib and most patients will eventually experience disease progression while on imatinib treatment. Sunitinib is approved for treatment of a GIST after disease progression on, or intolerance to, imatinib therapy. Progression may occur early or later on, in treatment and is determined by factors including initial GIST genotype and mutational status. GISTs with KIT exon 11 mutations appear to be sensitive to standard dose imatinib, and patients with GISTs exhibiting KIT exon 9 mutations whose disease has progressed on imatinib 400 mg/day have been shown to respond to imatinib 800 mg/day, albeit with a higher incidence of adverse events. Sunitinib has shown clinical benefit in all major GIST mutational subtypes, particularly in patients with wild-type or KIT exon 9 genotype and against GISTs with secondary KIT exon 13 or 14 mutations. The choice between higher-dose imatinib and sunitinib after progression on standard dose imatinib is unclear, and apart from the GIST primary resistance genotype and mutational status, individual patient factors such as tumour characteristics, drug pharmacokinetics, and other clinical factors may affect response to treatment. Individualisation of therapy may help to maximise clinical benefit of therapy in these patients.
authors.affiliation: HELIOS Klinikum Bad Saarow, Bad Saarow, Germany. peter.reichardt@helios-kliniken.de
authors.forename: Peter
authors.initials: P
authors.lastname: Reichardt
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D001549:Benzamides; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004252:DNA Mutational Analysis; D019008:Drug Resistance, Neoplasm; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000627:therapeutic use / Q000633:toxicity; D009154:Mutation; D009367:Neoplasm Staging; D010879:Piperazines / Q000627:therapeutic use / Q000633:toxicity; D011743:Pyrimidines / Q000627:therapeutic use / Q000633:toxicity; D011758:Pyrroles / Q000627:therapeutic use / Q000633:toxicity; D000077210:Sunitinib; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D000077210:Sunitinib
references.citation: Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34
references.pmid: 15451219
references.citation: J Clin Oncol. 2003 Dec 1;21(23):4342-9
references.pmid: 14645423
references.citation: Cancer Chemother Pharmacol. 2005 Apr;55(4):379-386
references.pmid: 15592836
references.citation: Clin Exp Metastasis. 2003;20(8):757-66
references.pmid: 14713109
references.citation: J Clin Oncol. 2009 Jul 1;27(19):3141-7
references.pmid: 19451435
references.citation: Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71
references.pmid: 19967539
references.citation: Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7
references.pmid: 19164557
references.citation: Blood. 2004 Nov 1;104(9):2940-2
references.pmid: 15251980
references.citation: Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):88-99
references.pmid: 18537751
references.citation: Eur J Cancer. 2009 Jul;45(11):1959-68
references.pmid: 19282169
references.citation: J Clin Endocrinol Metab. 2006 Oct;91(10):4070-6
references.pmid: 16849418
references.citation: Br J Cancer. 2008 Feb 26;98(4):684-8
references.pmid: 18253129
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Oct 15;874(1-2):84-8
references.pmid: 18823825
references.citation: J Clin Oncol. 2009 Jan 20;27(3):439-45
references.pmid: 19064982
references.citation: J Clin Oncol. 2008 Nov 20;26(33):5352-9
references.pmid: 18955458
references.citation: Mol Cancer Ther. 2003 May;2(5):471-8
references.pmid: 12748309
references.citation: Eur J Cancer. 2003 Sep;39(14):2006-11
references.pmid: 12957454
references.citation: J Gastrointest Surg. 2009 Sep;13(9):1583-92
references.pmid: 19291337
references.citation: Eur J Cancer. 2006 May;42(8):1093-103
references.pmid: 16624552
references.citation: Lancet. 2006 Oct 14;368(9544):1329-38
references.pmid: 17046465
references.citation: Clin Cancer Res. 2003 Feb;9(2):625-32
references.pmid: 12576428
references.citation: Expert Opin Investig Drugs. 2009 Apr;18(4):457-68
references.pmid: 19335275
references.citation: Ther Clin Risk Manag. 2008 Feb;4(1):149-62
references.pmid: 18728705
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5357-64
references.pmid: 15928335
references.citation: Invest New Drugs. 1992 Nov;10(4):239-53
references.pmid: 1487397
references.citation: Int J Cancer. 2005 Nov 1;117(2):289-93
references.pmid: 15900576
references.citation: J Clin Oncol. 2006 Oct 10;24(29):4764-74
references.pmid: 16954519
references.citation: Eur J Cancer. 2005 Dec;41(18):2868-72
references.pmid: 16293410
references.citation: J Clin Oncol. 2007 May 1;25(13):1760-4
references.pmid: 17470866
references.citation: Eur J Cancer. 2005 Aug;41(12):1751-7
references.pmid: 16098458
references.citation: Oncologist. 2007 Jun;12(6):719-26
references.pmid: 17602061
references.citation: J Clin Oncol. 2008 Feb 1;26(4):620-5
references.pmid: 18235121
references.citation: J Clin Oncol. 2007 May 1;25(13):1753-9
references.pmid: 17470865
references.citation: Cancer. 2005 Feb 15;103(4):821-9
references.pmid: 15648083
references.citation: Eur J Cancer. 2009 Sep;45(13):2293-7
references.pmid: 19467857
references.citation: Curr Oncol Rep. 2008 Jul;10(4):344-9
references.pmid: 18778561
references.citation: Blood. 2003 May 1;101(9):3597-605
references.pmid: 12531805
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 15;877(22):1982-96
references.pmid: 19505856
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5795-804
references.pmid: 16110036
references.citation: Lancet. 2009 Mar 28;373(9669):1097-104
references.pmid: 19303137
references.citation: Clin Cancer Res. 2003 Jan;9(1):327-37
references.pmid: 12538485
references.citation: Clin Cancer Res. 2005 Jun 1;11(11):4182-90
references.pmid: 15930355
references.citation: Hematol Oncol Clin North Am. 2009 Feb;23(1):139-50, x
references.pmid: 19248977
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: J Clin Oncol. 2008 Feb 1;26(4):626-32
references.pmid: 18235122
references.citation: Ann Oncol. 2009 May;20 Suppl 4:64-7
references.pmid: 19454466
references.citation: J Nucl Med. 2004 Mar;45(3):357-65
references.pmid: 15001674
references.citation: N Engl J Med. 2002 Aug 15;347(7):472-80
references.pmid: 12181401
references.citation: J Clin Oncol. 2008 Feb 1;26(4):570-6
references.pmid: 18235116